

## Basic Information

<b>Product Name</b>	Anti-Cytokeratin 19/KRT19 Antibody	
<b>Gene Name</b>	KRT19	
<b>Source</b>	Rabbit	
<b>Isotype</b>	IgG	
<b>Species Reactivity</b>	human, mouse	
<b>Tested Application</b>	WB, IHC, ICC/IF, FCM	
<b>Contents</b>	500 ug/ml; Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	
<b>Immunogen</b>	A synthesized peptide derived from human Cytokeratin 19	
<b>concentration</b>	500 ug/ml	
<b>Purification</b>	Affinity-chromatography	
<b>Observed MW</b>	44KD	
<b>Dilution Ratios</b>	Western blot (WB): 1:1000-5000 Immunohistochemistry in paraffin section (IHC): 1:20-100 Immunocytochemistry/Immunofluorescence (ICC/IF): 1:20-100 Flow cytometry (FCM): 1:20	


## Storage

12 months from date of receipt, -20°C as supplied. 6 months 2 to 8°C after reconstitution. Avoid repeated freezing and thawing.

## Background Information

Keratin, type I cytoskeletal 19 is a protein that in humans is encoded by the KRT19 gene. The protein encoded by this gene is a member of the keratin family. It is specifically expressed in the periderm, the transiently superficial layer that envelops the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21. Due to its high sensitivity, KRT19 is the most used marker for the RT-PCR-mediated detection of tumor cells disseminated in lymph nodes, peripheral blood, and bone marrow of breast cancer patients. Keratin 19 is often used together with keratin 8 and keratin 18 to differentiate cells of epithelial origin from hematopoietic cells in tests that enumerate circulating tumor cells in blood.

## Selected Validation Data



Western blot analysis of Cytokeratin 19 expression in HepG2 cell lysate.